Aortic Valve Disease | NYU Langone Health
NYU Langone cardiologists, cardiothoracic surgeons, and interventional cardiologists are highly trained in managing aortic valve disease.
Aortoiliac Occlusive Disease | NYU Langone Health
NYU Langone vascular specialists manage aortoiliac occlusive disease, which limits blood flow to the pelvis and legs.
APOL1 Long-term Kidney Transplantation Outcomes Network
The National Institutes of Health (NIH)-sponsored collaborative APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) is charged with prospectively assessing the effects of renal-risk variants (RRVs) in the apolipoprotein L1 gene (APOL1) on outcomes for kidneys from donors with recent African ancestry and the recipients of their kidneys, after deceased- and living-donor renal transplantation. For the purposes of APOLLO, recent African ancestry is defined as individuals with similar genetic make-up to those currently residing in Africa. APOLLO will also study the impact of APOL1 RRVs on the health of living kidney donors with recent African ancestry.
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1 BRCA2 or PALB2 Mutation
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.
Apps | NYU Langone Health
NYU Langone Health has launched several mobile apps to improve access to patient care and to conduct research studies.
AREN2231: Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)
This phase III trial studies using risk factors in determining treatment for children with favorable tissue (histology) Wilms tumors (FHWT). Wilms Tumor is the most common type of kidney cancer in children, and FHWT is the most common subtype. Previous large clinical trials have established treatment plans that are likely to cure most children with FHWT, however some children still have their cancer come back (called relapse) and not all survive. Previous research has identified features of FHWT that are associated with higher or lower risks of relapse. The term "risk" refers to the chance of the cancer coming back after treatment. Using results of tumor histology tests, biology tests, and response to therapy may be able to improve treatment for children with FHWT.
Arrange a Speaker from Perlmutter Cancer Center | NYU Langone Health
Experts from NYU Langone’s Perlmutter Cancer Center deliver educational programs to outside organizations through our speakers bureau.
Arrhythmias in Children | NYU Langone Health
Heart specialists at Hassenfeld Children’s Hospital at NYU Langone provide expert care for babies and children with arrhythmias.
Art Program | NYU Langone Health
The NYU Langone Art Program and Collection integrates artwork of the highest quality into the healing environments of our facilities.
Arthrogryposis in Children | NYU Langone Health
Doctors at Hassenfeld Children’s Hospital at NYU Langone give expert care to children with arthrogryposis, which affects joints and muscles.